3.43k followers • 31 symbols Watchlist by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies.
Curated by Yahoo Finance
Follow this list to discover and track large drug and biotechnology companies. These companies develop specialty drugs and treatments for various diseases and medical conditions. Although there are risks associated with the success of the drug, those that succeed tend to have a strong series of earnings growth over a period of time, especially when they are backed by patents.
The list includes stocks priced at $5 or more with a three month average daily trading volume in excess of 200,000 shares. This list is generated daily and sorted by market cap; the gains are based on the latest closing price and limited to the top 30 stocks that meet the criteria.
This watchlist is similar to a discontinued watchlist called Battling Cancer.
Yahoo Finance employs sophisticated algorithms to monitor and detect trends in the Global Financial Markets. We bring these insights to you in the form of watchlists.
Find other winning investment ideas with the Yahoo Finance Screener.How are these weighted?
The stocks in this watchlist are weighted equally.
|Watchlist||Change today||1-month return||1-year return||Total return|
|Biotech and Drug Stocks||+0.68%||-||-||-|
|Symbol||Company name||Last price||Change||% change||Market time||Volume||Avg vol (3-month)||Market cap|
|JNJ||Johnson & Johnson||159.92||+0.44||+0.28%||16:00 GMT-4||7.72M||8.21M||421.02B|
|RHHBY||Roche Holding AG||41.64||-0.05||-0.12%||16:00 GMT-4||926.76k||2.05M||285.29B|
|PFE||Pfizer Inc.||37.17||+0.01||+0.03%||16:02 GMT-4||23.35M||33.10M||207.34B|
|NVS||Novartis AG||86.75||+0.14||+0.16%||16:00 GMT-4||1.70M||2.00M||195.52B|
|MRK||Merck & Co., Inc.||76.4||-0.03||-0.04%||16:02 GMT-4||7.85M||12.08M||193.39B|
|ABBV||AbbVie Inc.||105.9||-1.02||-0.95%||16:02 GMT-4||6.78M||7.45M||186.90B|
|LLY||Eli Lilly and Company||183||+0.47||+0.26%||16:03 GMT-4||1.95M||4.50M||175.50B|
|NVO||Novo Nordisk A/S||70.55||-0.22||-0.31%||16:00 GMT-4||947.37k||1.02M||162.16B|
|AMGN||Amgen Inc.||249.62||-0.33||-0.13%||16:00 GMT-4||1.75M||2.77M||143.73B|
|BMY||Bristol-Myers Squibb Company||63.81||+0.23||+0.36%||16:00 GMT-4||7.33M||12.81M||142.55B|
|AZN||AstraZeneca PLC||49.84||+0.65||+1.32%||16:00 GMT-4||11.86M||11.07M||131.09B|
|GSK||GlaxoSmithKline plc||36.13||+0.09||+0.25%||16:00 GMT-4||4.26M||6.04M||89.33B|
|GLAXF||GlaxoSmithKline plc||17.815||+0.02||+0.11%||13:41 GMT-4||26.65k||419.55k||89.21B|
|GILD||Gilead Sciences, Inc.||65.3||+0.41||+0.63%||16:00 GMT-4||5.65M||8.65M||82.22B|
|ZTS||Zoetis Inc.||163.08||-0.39||-0.24%||16:04 GMT-4||1.15M||2.10M||77.46B|
|MRNA||Moderna, Inc.||160.03||+10.32||+6.89%||16:00 GMT-4||15.39M||11.93M||64.10B|
|BAYRY||Bayer Aktiengesellschaft||15.87||+0.03||+0.19%||15:59 GMT-4||278.10k||477.84k||62.08B|
|VRTX||Vertex Pharmaceuticals Incorporated||217.13||+1.19||+0.55%||16:00 GMT-4||1.43M||2.09M||56.20B|
|WXXWY||WuXi Biologics (Cayman) Inc.||27.15||+0.23||+0.85%||15:55 GMT-4||154.63k||415.60k||55.76B|
|TAK||Takeda Pharmaceutical Company Limited||17.06||+0.06||+0.35%||16:00 GMT-4||2.27M||4.06M||53.74B|
|REGN||Regeneron Pharmaceuticals, Inc.||481.16||+4.12||+0.86%||16:00 GMT-4||551.79k||1.05M||51.55B|
|BIIB||Biogen Inc.||265.79||-0.40||-0.15%||16:00 GMT-4||645.20k||1.31M||40.49B|
|ALXN||Alexion Pharmaceuticals, Inc.||155.29||+1.56||+1.01%||16:00 GMT-4||2.04M||2.75M||34.14B|
|BNTX||BioNTech SE||132.6||+2.96||+2.28%||16:00 GMT-4||3.34M||1.91M||32.03B|
|BGNE||BeiGene, Ltd.||300.65||+0.34||+0.11%||16:00 GMT-4||162.89k||327.94k||27.32B|
|SGEN||Seattle Genetics, Inc.||144.2||+3.31||+2.35%||16:00 GMT-4||841.42k||1.20M||26.14B|
|RPRX||Royalty Pharma plc||42.12||+0.69||+1.67%||16:00 GMT-4||2.58M||3.24M||25.57B|
|GMAB||Genmab A/S||34.67||+0.02||+0.06%||16:00 GMT-4||314.59k||667.06k||22.50B|
|HZNP||Horizon Pharma Public Limited Company||91.45||-0.17||-0.19%||16:00 GMT-4||1.56M||2.07M||20.50B|
Dr. Owais Durrani, Emergency Medicine Resident Physician, UT Health San Antonio, joined Yahoo Finance Live to break down the upsides of Americans being overly cautious of the COVID-19 vaccine.
"Discussions now are really turning to 2022, and governments being worried about boosts," Stephane Bancel told Yahoo Finance.
Swiss drugmaker Novartis has signed a deal to make ingredients for Roche's Actemra treatment that is being repurposed for people with COVID-19, the company said on Thursday. The arrangement is the third transaction signed by Novartis following agreements with BioNTech and CureVac to make therapies for other firms to help fight the pandemic. Actemra is a treatment for rheumatoid arthritis which is also being tested in various clinical trials to treat COVID-19 associated pneumonia.